8YY.SI - Biolidics Limited

SES - SES Delayed Price. Currency in SGD
Currency in SGD

Valuation measures4

Market cap (intra-day) 9.51M
Enterprise value 7.49M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)1.92
Price/book (mrq)N/A
Enterprise value/revenue 2.41
Enterprise value/EBITDA -0.95

Trading information

Stock price history

Beta (5Y monthly) 0.75
52-week change 3-82.35%
S&P500 52-week change 32.74%
52-week high 30.0860
52-week low 30.0140
50-day moving average 30.0164
200-day moving average 30.0252

Share statistics

Avg vol (3-month) 32.64M
Avg vol (10-day) 3618.55k
Shares outstanding 5559.13M
Implied shares outstanding 6N/A
Float 8422.34M
% held by insiders 126.89%
% held by institutions 11.63%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Mar 2023


Profit margin -268.88%
Operating margin (ttm)-154.96%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)-1,275.15%

Income statement

Revenue (ttm)3.17M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)132.20%
Gross profit (ttm)-128k
Net income avi to common (ttm)-8.52M
Diluted EPS (ttm)-0.0300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.83M
Total cash per share (mrq)0.01
Total debt (mrq)2.75M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.08
Book value per share (mrq)-0.00

Cash flow statement

Operating cash flow (ttm)-2.34M
Levered free cash flow (ttm)N/A